Biomarker Analysis: Pharmacodynamic Monitoring

Extract the maximum pharmacodynamics (PD) information from limited sample volumes.Biomarker-1

Biomarker analysis provides prognostic, predictive, pharmacodynamic or surrogate endpoint information for a therapeutic intervention. Biomarker analysis can also assist in understanding the mode of action, target engagement in response to therapeutic administration, and pharmacokinetic (PK) endpoints.

Precise immunoassay methods are needed to measure biomarkers with qualification of performance characteristics that are fit for purpose to support different stages of biotherapeutic development. Biomarker immunoassays for preclinical safety toxicology studies require large sample volumes that necessitate pooling samples from multiple mice, have lengthy assay times, and lack dynamic range and sensitivity to meet study requirements. High MRDs and slow assay development also hinder biomarker fit-for-purpose assay development.

Gyroplex Panels

Gyrolab technology provides rapid and precise biomarker monitoring that addresses these challenges. The recent introduction of the Gyrolab Bioaffy™ 4000 CD expands Gyrolab assay sensitivity for a more powerful solution to biomarker analysis.

  • High sensitivity & dynamic range
    Limits of quantitation down to sub-pg/mL levels
  • Rapid time to results
    Results in about one hour with automated assay workflow
  • Minimal sample dilution
    Reduce sample MRDs while minimizing matrix effects with affinity flow-through format and short contact times 
  • Low sample consumption, multiple cytokine assays run in parallel
    As low as 4 µL of sample for duplicates maximizes analyses from limited serum samples 
  • Biomarker panels run precisely
    Separate reactions with results with high sensitivity and assay quality

Low sample volume requirements also allows for multiple analyte measurements from as little as 12 µL. Whether in discovery or in the regulated environment, biomarker assays using Gyrolab platforms positively impact sensitivity, throughput, performance and productivity in the development of therapeutics.

Gyrolab assay protocols are available for these biomarkers to accelerate assay development:

Human IFN-gamma Human IL-8 Mouse Erythropoietin (EPO) Complement TCC
Human IL-1 beta Human IL-10 Rat Erythropoietin (EPO) Clusterin
Human IL-2 Human IL-13 Rat KIM-1 GLP-1 Active
Human IL-4 Human TNF-alpha Calprotectin GLP-1 Total

Human IL-6

Human VEGF Assay Complement C4d  


 Want to learn more? Speak to our scientists about your application.
Talk To Our Scientists
    Gyrolab Systems
    Gyrolab technology reduces manual labor, assay development time, time to result and material consumption -and it improves workflow efficiency. 

    Maximizing productivity in biopharmaceutical research and clinical development
    Three case studies are presented: "Obtaining an entire PK profile form a single mouse", "Earlier and more sensitive detection of drug-induced kidney toxicity in preclinical studies" and "Ramping up Phase II/III PK studies to meet critical deadlines". 
    [Application Note]

    Mark Dysinger GLP-1 quantitation: Gyros vs. other detection platforms
    Recorded Seminar: Mark Dysinger, Senior Scientist, Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, presents ‘Glucagon-Like Peptide 1 Quantitation: Gyros vs Other Detection Platforms'. 

    Diane Hamlin on the performance of Gyrolab xP workstation
    Recorded Seminar: Diane Hamlin, Eli Lilly and Company, presents 'Performance of the Gyrolab xP System for Custom Development of Preclinical Urinary Renal Biomarker Assays'. 

    Rapid Reagent Screening and Characterization using Automated Nanoliter-scale Immunoassays
    Recorded Webinar: Gyrolab is a reliable immunoassay platform that streamlines reagent selection and characterization during method development for biotherapeutics. Presenters: Frank Zambito, Research Scientist I, Bioanalytical Sciences, Bristol-Myers Squibb and Shawn Fernando, Senior Principal Researcher, Morphotek, Inc. 

    Using Automated Nanoliter-Scale Immunoassays for Improved Performance and Efficiency
    Recorded Webinar: Christophe Henry, Ph.D., Laboratory Head / Translational Medicine, Sanofi, presents case studies featuring reagent screening and method development for a variety of different biotherapeutics – traditional and non-conventional constructs. 

    Redefining 3Rs for Safety Toxicology Biomarkers using Automated Nanoliter-scale Immunoassays
    Recorded Webinar. Presenters: Diane Marie Hamlin, Investigative Toxicology, Eli Lilly and Wei Zheng, Immunoassays & Multiplexing, Bioscience, EMD Millipore. 

    Fit-for-Purpose Biomarker Assay Development and Validation using Automated Nanoliter-Scale Immunoassays
    Recorded Webinar. Presenters: Robert Durham, Ph.D., Gyros Inc., Chad A. Ray, PhD, Pfizer PDM, Kerry Oliver, Ph.D., Radix Biosolutions & Ariëlla Van de Sompel, Senior Research Associate, Ablynx. 

    A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma96
    Please visit the recorded webinar. Presenter Mark Dysinger, M.S., Development Scientist III, Alexion Pharmaceuticals 

    Accelerating workflows for calprotectin and complement (C4d, TCC) biomarker immunoassays
    Recorded webinar: automated immunoassays for complement analytes C4d and TCC and calprotectin using Svar Life Science Flexi reagents and Gyrolab® platform 

    Rapid and sensitive multi-biomarker analysis powered by Gyroplex™ panels on Gyrolab® Bioaffy™ 4000 CD
    [Application Note]